window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : January 31, 2026

  • News
  • About Us
Contact Us

seed financing

  • Biotech,Cell & Gene Therapy,Drug Development,Healthcare leadership,Immunology

    TECregen appoints Dr Klaas Zuideveld as CEO to advance thymus regeneration platform

    TECregen has appointed Dr Klaas Zuideveld as chief executive officer [...]

    January 29, 2026
  • Biotech,Clinical Trials,Funding,Pharmaceuticals and therapeutics

    Infinitopes raises $35 million seed round to advance precision cancer vaccine

    Infinitopes, a clinical-stage biotech developing precision cancer vaccines, has completed [...]

    January 21, 2026
  • Biologics & Biosimilars,Biotech,Immunology,Partnerships & Funding,Research & Development

    TECregen raises CHF 10m (EUR 10.7m) seed financing and appoints Dr Bo Rode Hansen as chairman

    TECregen, a biotechnology company focused on thymus regeneration, has completed [...]

    January 8, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Evestia Clinical acquires ICRC-Weyer to expand full-service clinical research in Europe
    Categories: Biotech, CDMOs & Manufacturing, Clinical Development, Clinical Trials, Partnerships & Funding
  • Mental health systems strain as demand and funding shifts drive push for multimodal care
    Categories: Digital Health, Healthcare leadership, Medical devices, Mental health, Regulatory Affairs
  • Nine-gene signature linked to lapatinib resistance in HER2-positive breast cancer
    Categories: Clinical studies, Drug Development, Oncology, Precision medicine, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top